Business Wire

Modalis Therapeutics to Present Data Supporting of Development of Transformative Epigenetic Editing Medicines for the Treatment of a Type of Muscular Dystrophy at the ASGCT ...

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...
Medical Xpress

First successes in the development of a gene therapy for incurable LAMA2-related muscular dystrophy

Researchers at the University of Basel have developed a gene therapy that could potentially treat a rare and currently fatal muscle disease in children. The study shows in animal models that a single ...
WAVY-TV

Sarcomatrix Renews United States Orphan Drug Designation for LAMA2-Related Muscular Dystrophy Program

RENO, NV, UNITED STATES, April 9, 2025 /EINPresswire.com/ -- Sarcomatrix Therapeutics, a privately held biopharmaceutical company advancing transformative therapies ...
WNCT

Sarcomatrix Renews EU Orphan Drug Status for LAMA2-RD and Expands Research into Duchenne Muscular Dystrophy Treatment

The renewal highlights ongoing progress in developing rhLAM-111 for rare muscular diseases, with a new emphasis on Duchenne Muscular Dystrophy. We are excited to have renewed our EU Orphan Drug ...
technologynetworks

Gene Therapy Shows Promise for Fatal Childhood Muscle Disease

Roughly once a year in Switzerland, a family receives the devastating diagnosis that their child is affected by a severe form of muscle weakness. This hereditary disease, known as LAMA2-related ...
The Brown Daily Herald

Professor tests muscular dystrophy treatment

Justin Fallon, professor of medical science, has been conducting research on Duchenne muscular dystrophy for 25 years. Now, with the help of external partnerships, his discoveries could be employed in ...